1. Home
  2. TLSI vs FINW Comparison

TLSI vs FINW Comparison

Compare TLSI & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.33

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Logo FinWise Bancorp

FINW

FinWise Bancorp

HOLD

Current Price

$11.32

Market Cap

194.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLSI
FINW
Founded
2010
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
270.2M
194.1M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
TLSI
FINW
Price
$4.33
$11.32
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
★ $7.00
N/A
AVG Volume (30 Days)
★ 253.1K
33.6K
Earning Date
05-12-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.51
EPS
N/A
★ 0.35
Revenue
★ $45,151,000.00
N/A
Revenue This Year
$35.45
$160.48
Revenue Next Year
$37.58
$35.27
P/E Ratio
★ N/A
$32.54
Revenue Growth
★ 53.41
N/A
52 Week Low
$2.20
$10.79
52 Week High
$7.95
$20.38

Technical Indicators

Market Signals
Indicator
TLSI
FINW
Relative Strength Index (RSI) 36.21 18.68
Support Level $4.28 N/A
Resistance Level $4.47 $14.62
Average True Range (ATR) 0.35 0.51
MACD -0.07 -0.17
Stochastic Oscillator 16.29 15.08

Price Performance

Historical Comparison
TLSI
FINW

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

Share on Social Networks: